Biomind Labs At PSYCH Symposium Biomind Labs announced it was relocating from Toronto to Cambridge, recognising the opportunities in Europe’s

Negev Capital With US$30 million under its management, Negev Capital is a fund focused on psychedelic drug development, with investments

At the start of 2022, the FDA cleared MindMed’s Investigational New Drug (IND) application for MM-120, paving the way for

Psilocybin was first isolated in 1958 by Albert Hofmann and is one of the most researched psychedelic medicines, with over

At the PSYCH Symposium on 11 May, industry leaders will connect and collaborate to expedite access to psychedelic-based healthcare across